DGAP-Adhoc: 4SC AG decides on an increase in share capital

| Source: EQS Group AG EQS Group AG 

4SC AG / Capital Increase

20.06.2008 

Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

Planegg-Martinsried, Germany, 20 June 2008 – Today, the Management Board of
the Martinsried-based drug discovery and development company 4SC AG
(Frankfurt, Prime Standard: VSC), with the approval of the Supervisory
Board, decided to increase the share capital from 19,001,826.00 Euros to up
to 28,502,739.00 Euros, by issuing up to 9,500,913 zero par value common
bearer shares from the authorised capital.
The new shares are to be offered to the shareholders at a subscription
price of 3.10 Euros per new share.

The proceeds of the capital increase are to be used for financing the
acquisition of Nycomed’s oncology projects in the amount of 14 million
Euros (compare Ad Hoc announcement of 4SC AG dated 4 June 2008) and to
further develop the existing as well as the new project pipeline of 4SC AG.

The subscription rights of the shareholders are complied with. The
shareholders can subscribe to the new shares with dividend rights from 1
January 2008 in a 2:1 ratio starting from 25 June 2008 until 10 July 2008.
In the following unsubscribed shares are to be offered to institutional
investors. A public offer for the purchase of the new shares is not
planned. The admission of the new shares for trading at the Frankfurt Stock
Exchange is not expected before November/December 2008.

Further details of the capital increase will be provided in the
subscription offer expected to be published in the electronic Federal
Gazette on 25 June 2008.

---------------------------------------------------------------------------

Information and Explaination of the Issuer to this News:

About 4SC AG:
4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of
Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now
with a staff of 74, the company develops novel drug candidates for
inflammatory diseases, cancer and infectious diseases using a
cheminformatics based technology platform. Traditional high throughput
screening of therapeutic agents has been transferred from the lab to the
computer. Thus, the company offers substantial cost and time advantages as
well as increased success rates in drug development. 4SC AG utilises its
technology platform, which is protected by patent, to create a sustainable
project pipeline of active agents to be developed up to the early clinical
phases ('proof of concept') and subsequently licensed to the pharmaceutical
industry in return for advance and milestone payments as well as royalties.
There are currently six projects in the pipeline and a so-called ideas’
pool with further development candidates. The first project for the
treatment of rheumatoid arthritis has already successfully completed
clinical phase IIa. Four other product candidates are in pre-clinical
development and another project is in the research stage. In addition, the
company is implementing its technology platform in partnerships with
pharmaceutical and biotechnology companies, and is already generating
initial revenues.


Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.


Bettina von Klitzing 
Manager Investor Relations & Public Relations
4SC AG 
Tel.: +49 (0) 89 70 07 63 - 0 
Bettina.von.Klitzing@4sc.com 


DGAP 20.06.2008 
---------------------------------------------------------------------------
Language:     English
Issuer:       4SC AG
              Am Klopferspitz 19a
              82152 Martinsried
              Deutschland
Phone:        +49 (0)89 7007 63-0
Fax:          +49 (0)89 7007 63-29
E-mail:       public@4sc.com
Internet:     www.4sc.de
ISIN:         DE0005753818
WKN:          575381
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, München, Stuttgart
End of News                                     DGAP News-Service
---------------------------------------------------------------------------